Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The vast majority of patients with ALL will die of the disease, and no standard chemotherapy
regimen were defined for patients with relapsed/refractory ALL.Our previous experience has
shown that Cladribine in combination of GAP (G-CSF priming, low dose cytarabine, and
Pegaspargase) are effective with tolerable toxicity profiling.Thus, this phase 2 clincial
trial is going to evaluate the efficacy and safety of cladribine in combination with G-CSF,
low-dose cytarabine and Pegaspargase (C-GAP) in patients with refractory/relapsed acute
Lymphoblastic Leukemia